Zusammenfassung
The pharmaceutical industry has passed a consolidation phase, which is delayed in comparison to other industries, but it follows the same mechanics. Whereas the primary consolidation most often can be seen in the form of elevated M&A transactions, the far-reaching secondary transformation also affects the value chain and the business model of the (pharmaceutical) industry itself. Like in other industries, the value chain of the pharmaceutical industry has become subject to enormous pressure, which is leading to new arrangements of ownership and geographic allocation of value chain activities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literaturverzeichnis
Asia Pacific Biotech News: Asia Pacific Biotech News 8/30/2006, Vol. 10 (2006), Issue 16, pp. 866-866, 1/3p
Bakhle, D.: Global Clinical Trials in India – Challenges and Opportunities, Business Briefing: Phamatech 2003, pp. 109-110
CFO Research Services; A.T. Kearney: Outsourcing Among Pharmaceutical And Biotech Firms - The Growing Imperative for a More Aggressive Approach to Outsourcing, report, CFO Publishing Corp., 2004
Cruickshank, C.; Bailey, W.; Sharma, N.: Pharmaceutical Executive; June 2006 Supplement, Vol. 26 (2006), pp. 14-19
Garg, R.: Four Opportunities in India’s pharmaceutical market, in: McKinsey Quarterly 1996 Number 4, pp. 132-145
Gross, A.: Outsourcing to Asia, Presentation to Barnett International, May 12, 2005
Häussler, B.; Helberger, C.: Auftragsforschungsinstitute (CROs) in Deutschland, in: Pharm.Ind., Vol. 63 (2001), No. 10, pp. 1011-1017
Jarvis, L.: Chemical Market Reporter; 12/5/2005, Vol. 268 (2005), Issue 19, pp. 32-33
Knowledge@Wharton IN COLLABORATION WITH Bain & Company: Where will Indian drug companies be in five years? Everywhere – if they innovate, Survey report 2006
KPMG: India Pharma Inc – Leveraging Emerging Opportunities, Pharma Summit 2004
Lustgarten, A.; Cherry, B.: Fortune 8/8/2005, Vol. 152 (2005), Issue 3, pp. 56-61
O. V.: Cost of development soars to $802 million per drug, Scrip Daily News Alert, Ref: 58510, PJB Publications 2001, pp. 1-3
Paddison, C.; White, C.; Cruickshank, C.: Outsourcing Beyond the Comfort Zone, in: Pharmaceutical Technology, Aug 1, 2005
Padma, T. V.: Nature Vol. 436, 28 July 2005, p485
Rajan, G. R.: Making India a global hub, in: McKinsey Quarterly 2005 special edition: Fulfilling India’s promise, 2005, pp. 113-121
Schnoor, C.; Brückner, M.: Management von Auftragsforschungsinstituten im Zeitalter des Internet, in: Pharm. Ind., Vol. 63 (2001), No. 12, pp. 1231-1236
Specialty Chemicals: May2005, Vol. 25 Issue 4, p. 6
Turcq, D.: India & China – Asia’s non-identical twins, in: McKinsey Quarterly, 1995, Number 2, pp. 4-19
Varawalla, N.: Will India Become the Outsourcing Capital fort he Global Pharmaceutical Industry?, in: European Pharmaceutical Contractor Autumn/Winter ’04 issues
Editor information
Rights and permissions
Copyright information
© 2008 Gabler | GWV Fachverlage GmbH
About this chapter
Cite this chapter
Nagels, K.H. (2008). Pharmaceutical R&D Globalization continued. In: Da-Cruz, P., Cappallo, S. (eds) Gesundheitsmegamarkt Indien. Gabler. https://doi.org/10.1007/978-3-8349-8777-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-8349-8777-8_7
Publisher Name: Gabler
Print ISBN: 978-3-8349-0745-5
Online ISBN: 978-3-8349-8777-8
eBook Packages: Business and Economics (German Language)